Yazar "Tay, A." seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly(Springer Heidelberg, 2017) Tuzcu, S.; Durmaz, S. A.; Carlioglu, A.; Demircan, Z.; Tuzcu, A.; Beyaz, C.; Tay, A.Objective. Growth hormone (GH) and insulinlike growth factor-1 (IGF-1) play a major role in bone homeostasis. In this study, we aimed to assess bone mineral density (BMD) in active acromegaly. Materials andmethods. A total of 29 patients with active acromegaly (age 46.10 +/- 13.27 years; body mass index [BMI]: 29.51 +/- 4.91 kg/m(2)) and 42 healthy individuals matched for age and BMI (age: 40.35 +/- 11.74 years; BMI: 28.18 +/- 7.35 kg/m(2)) were included in the study. BMD wasmeasured by DXA. Results. The mean levels of GH and IGF1 were found to be 12.61 +/- 11.34 ng/ml and 676.47 +/- 316.19 ng/ml in acromegaly, respectively, while the mean levels of GH and IGF-1 were found to be 0.59 +/- 0.81 ng/ml (p = 0.0001) and 178.17 +/- 57.11 ng/ml (p = 0.0001) in the control group, respectively. Only total hip t-score was determined to be significantly lower in acromegaly compared to the control group (p = 0.037). No significant differences were found between the other parameters in DXA and only a positive correlation was found between IGF-1 levels and L1-L4 BMD (r = 0.259, p = 0.029). Conclusions. Although GH and IGF-1 levels were increased in acromegalic patients, no significant difference was found in terms of vertebral BMD. Only hip t-scores were found to be lower in acromegalic patients, but this low hip t-score did not reach the osteopenic level. The positive correlation between IGF-1 and lumbar vertebral BMD suggested a more prominent effect of IGF-1 on BMD compared to GH.Öğe Relationship between nitric oxide, asymmetric dimethylarginine levels and diabetic neuropathy(Springer Heidelberg, 2013) Tamam, Y.; Uzar, E.; Evliyaoglu, O.; Tay, A.; Kilinc, F.; Cevik, M.[Abstract Not Available]Öğe Serum myeloperoxidase levels in predicting the severity of stroke and mortality in acute ischemic stroke patients(Verduci Publisher, 2015) Tay, A.; Tamam, Y.; Yokus, B.; Ustundag, M.; Orak, M.OBJECTIVE: The aim of this study was to examine the level of myeloperoxidase (MPO) measured before specific treatment in patients presenting to the Emergency Department with acute ischemic stroke and its correlation to mortality and the severity of the stroke. PATIENTS AND METHODS: The study was carried out on 55 patients with a confirmed diagnosis of ischemic stroke, and on 44 healthy control group. Before specific intervention, serum samples were taken to measure levels of MPO. The medical records, demographic, clinical, laboratory and neuro-imaging data were noted. The National Institutes of Health Stroke Scale was used to determine the severity of the stroke. RESULTS: A total of 55 patients, of whom 32 (58.2%) were male, who had presented within 24 hours of the onset of symptoms of acute ischemic stroke were included in the study. Fifteen of these patients (27.2%), of whom five were women, died. There was a statistically significant difference in the serum MPO levels of patients who survived and those who died. When the patients were grouped as high or normal in terms of plasma MPO levels, a significant correlation was found between MPO level, cortical + subcortical stroke location and strokes with a lesion diameter of more than 4 cm. In the high MPO group, Troponin T and CRP levels were significantly higher than those of the normal MPO group. CONCLUSIONS: The level of myeloperoxidase in the serum of acute ischemic stroke patients rises and there is a correlation between myeloperoxidase level and prognosis.
